Hepatitis C virus (HCV) infection i...

Hepatitis C virus (HCV) infection is the in the greatest degree common blood-borne infection. It affects approximately 18 percent of the U population (38 million bodily forms exposed and 2.7 million bodily forms chronically infected). (1) Most cases of chronic HCV infection have over and above to be diagnosed. Therefore, a substantial increase in the number of known cases is concocted over the next decade, along with a large increase in the number of patients with complications of HCV infection, as it is as cirrhosis, liver failure, and hepatocellular carcinoma. HCV infection already is the leading cause of chronic liver disease in patients presenting to gastroenterologists, the leading cause of hepatocellular carcinoma, and the leading diagnosis among patients referr for liver transplantation. (2)

Because of the increasing prevalence of chronic HCV infection and significant advances in its diagnosis and treatment, this illness has been the expose of several recent reviews (34) and a consensus statement from the National Institutes of Health (NIH). (5) This article reviews factors that should be considered in the evaluation of the suitability of HCV-infected patients for treatment.

Natural History of HCV Infection

Acute HCV infection is rarely rigid and usually asymptomatic. Although the immune plan occasionally eradicates the virus, up to 85 percent of patients bring out chronic HCV infection (Figure 1) (12) above time, liver damage and other sequelae increase, and patients begin to have symptoms. Risk factors for more rapid progression of disease include age throughout 40 years at the time of infection, male inflection for sex and daily consumption of more than 30 g of alcohol. (5-7)

[FIGURE 1 OMITTED]

Although greatest in number HCV-related deaths occur after the disease has increaseed to cirrhosis, (7) patients can have significant symptoms and reduction in quality of life well before that time. (8) Chronic HCV infection also is linked to an increased incidence of several extrahepatic diseases, including renal disease, diabetes mellitus, neuropathy, lymphoma, Sjogren's syndrome mixed cryoglobulinemia, and porphyria cutanea tarda. (9)

Advances in Diagnosis and Treatment

across the past 15 years, remarkable advancements have been made in the identification of HCV infection. The screening of donated kin for HCV RNA has reduc the risk of viral transmission from one side blood transfusions to less than united case per 100,000 units of family transfused. (10) The efficacy of treatment also has improved. First, interferon was used, then interferon in combination with ribavirin; the latest treatment, a combination of pegylated interferon with ribavirin, is clearly superior to the older regimens and is the passing from hand to hand standard of care. (11,12)

The NIH guideline (5) onward the management of HCV infection proposes that all patients with chronic infection are potential candidates for antiviral therapy, and especially make acceptables treatment for patients with an increased risk of developing cirrhosis.

Diagnosis of HCV Infection

A third-generation HCV antibody experiment (at least 99 percent sensitive, 99 percent specific) is commended for use as the initial touchstone in patients with clinical or laboratory evidence of liver disease and for the screening of at-risk populations. (5) The Center for Disease repress and Prevention (CDC) recommends screening in asymptomatic human frames who have any of the following risk factors: history of intravenous unsalable article use, blood transfusion or organ transplant before 1992 receipt of clotting factors before 1987 or long-term hemodialysis. (13) [SORT C: consensus/expert opinion]

The anti-HCV antibody example determines whether a person evermore has been exposed to HCV on the other hand not the presence of active infection (because 15 to 20 percent of bodily substances who contract HCV spontaneously clear the infection). False-positive consequence s are possible, especially when the exhibition is used as a screening tool in a population with a relatively grave risk of disease. False-negative terminates may occur in immunosuppressed persons

Active infection therefore must be confirmed from demonstrating the presence of HCV RNA. Quantitative standards detect and count viral loads as subdued as 50 to 500 copies by mL, whereas qualitative tests expose (but do not quantify) the port of HCV in the range of 5 to 50 copies by mL. (14) Confirmation of the diagnosis requires simply a single positive test showing the demeanor of HCV RNA. Because there can be a transient decline in viremia to below the flush of assay sensitivity, all negative touchstone results should be reconfirmed with another proof approximately one month later to be certain that active HCV infection is not current (5) An algorithm for the diagnosis of chronic HCV infection in patients with risk factors or clinical or laboratory evidence of liver disease is provided in Figure 2 (12)

[FIGURE 2 OMITTED]

Evaluation of Patients with Chronic HCV Infection

HISTORY OF HCV INFECTION

most numerous patients with HCV infection are asymptomatic, and the diagnosis usually is made after transaminase screening. However, a certain number of patients have evidence of advanced disease, with symptoms of liver failure. Fatigue and nausea fall out in many patients, but these symptoms are not unique to HCV infection.